Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HCW Biologics (HCWB) Non-Current Assets (2020 - 2025)

Historic Non-Current Assets for HCW Biologics (HCWB) over the last 6 years, with Q3 2025 value amounting to $23.9 million.

  • HCW Biologics' Non-Current Assets fell 247.39% to $23.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $98.8 million, marking a year-over-year increase of 375.26%. This contributed to the annual value of $24.5 million for FY2024, which is 1098.45% up from last year.
  • HCW Biologics' Non-Current Assets amounted to $23.9 million in Q3 2025, which was down 247.39% from $26.0 million recorded in Q2 2025.
  • Over the past 5 years, HCW Biologics' Non-Current Assets peaked at $26.0 million during Q2 2025, and registered a low of $3.0 million during Q2 2021.
  • For the 5-year period, HCW Biologics' Non-Current Assets averaged around $18.8 million, with its median value being $21.9 million (2023).
  • Per our database at Business Quant, HCW Biologics' Non-Current Assets skyrocketed by 32784.73% in 2022 and then tumbled by 387.37% in 2023.
  • HCW Biologics' Non-Current Assets (Quarter) stood at $13.0 million in 2021, then dropped by 2.27% to $12.7 million in 2022, then skyrocketed by 73.57% to $22.1 million in 2023, then increased by 10.98% to $24.5 million in 2024, then fell by 2.78% to $23.9 million in 2025.
  • Its last three reported values are $23.9 million in Q3 2025, $26.0 million for Q2 2025, and $24.4 million during Q1 2025.